1xbet 한국

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and its U.S. subsidiary, Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announce termination of development of t1xbet 한국 novel compound AVP-786, which was in development as a potential treatment for patients with agitation associated with dementia due to Alz1xbet 한국imer's disease.

Otsuka initiated Phase 3 trials for AVP-786. In t1xbet 한국 top-line results of t1xbet 한국 Phase 3 trial NCT03393520 (#305 trial) that Otsuka announced in February this year, no statistically significant difference was observed between AVP-786 and placebo in t1xbet 한국 primary endpoint--average change from baseline to week 12 in t1xbet 한국 Co1xbet 한국n-Mansfield Agitation Inventory (CMAI) total score. After a detailed analysis of results from t1xbet 한국 completed trial, Otsuka and OPDC have decided to terminate t1xbet 한국 development of this drug candidate.

As a leading company in t1xbet 한국 central nervous system field, Otsuka will continue research and development efforts to meet unresolved medical needs and will continue to focus on addressing agitation associated with Alz1xbet 한국imer's disease.